Source: http://www.patentgenius.com/patent/8268871.html
Timestamp: 2018-04-25 06:55:39
Document Index: 375970955

Matched Legal Cases: ['art 4', 'Application No. 05819172', 'Application No. 200580043628', 'Application No. 2007', 'Application No. 094136480', 'Application No. 200744612']

Mitotic kinesin inhibitors and methods of use thereof - Patent # 8268871 - PatentGenius
Mitotic kinesin inhibitors and methods of use thereof
8268871 Mitotic kinesin inhibitors and methods of use thereof
Inventor: Hans, et al.
Application: 12/822,066
Inventors: Hans; Jeremy (Longmont, CO)
Wallace; Eli M. (Lyons, CO)
Zhao; Qian (Superior, CO)
Allen; Shelley (Loveland, CO)
Laird; Ellen (Longmont, CO)
Lyssikatos; Joseph P. (Piedmont, CA)
Robinson; John E. (Commerce City, CO)
Corrette; Christopher P. (Arvada, CO)
DeLisle; Robert Kirk (Longmont, CO)
Voegtli; Walter C. (Lafayette, CO)
Assignee: Array BioPharma Inc. (Boulder, CO)
Primary Examiner: Anderson; Rebecca
Attorney Or Agent: Moore; John R.Williams; Corey M.
U.S. Class: 514/363; 548/136
Field Of Search: 514/363; 548/136
International Class: A61K 31/41; C07D 417/04
Foreign Patent Documents: 0531906; 1004241; 1671957; 2005-232016; 93/22311; WO 9322311; 98/38177; 01/56994; 03/051854; 03/079973; 2004/092147; 2004/111023; 2004/111024; WO 2005/017190; 2005/035512; 2005/092304; 2006/031348; WO 2006/044825; WO 2008/042928
Other References: Askari et al., Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), (1981), (2), 360-5.cited by examiner.
Moss et al., Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999) (1982), (9), 1987-91. cited by examiner.
Cancer and Metastasis Reviews (1998), 17(1), 91-106. cited by examiner.
Science (1999), vol. 286, 531-537. cited by examiner.
Bryn et al., "Chapter 11: Hydrates and Solvates" Solid-State Chemistry of Drugs, Second Edition, 1999, pp. 233-247. cited by other.
Golub et al., "Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring", Science, 1999, vol. 286, pp. 531-537. cited by other.
Lala et al., "Role of Nitric Oxide in Tumor Progression: Lessons from Experimental Tumors" Cancer and Metastasis Reviews, 1998, 17(1), pp. 91-106. cited by other.
Moss et al., Thiadiazoles and Thiadiazolines. Part 4. Acetylation, Hydrolysis, and Cyclocondensations of .DELTA.2-1 ,3,4-Thiadiazoline-a-carboxamidines, J. Chem. Soc., Perkin Trans. I, (1982) , pp. 1993-1998. cited by other.
Szczepankiewicz et al., "New Antimitotic Agents with Activity in Multi-Drug Resistant Cell Lines and in Vivo Efficacy in Murine Tumor Models", Journal of Medicinal Chemistry, 2001, 44(25), 4416-4430. cited by other.
Extended European Search Report Corresponding to Related European Application No. 05819172.7 dated Sep. 18, 2009. cited by other.
First Office Action Corresponding to Related Chinese Patent Application No. 200580043628.9 dated Jun. 5, 2009. cited by other.
Notice of Reasons for Rejection Corresponding to Related Japanese Patent Application No. 2007-537010 dated Aug. 5, 2011. cited by other.
Examination Report Corresponding to Related Taiwanese Patent Application No. 094136480 received Jan. 5, 2012. cited by other.
International Search Report Corresponding to Related PCT Application No. PCT/US2005/37305 dated Jul. 14, 2006. cited by other.
International Search Report Corresponding to Related PCT Application No. PCT/US2006/016526 dated Aug. 22, 2006. cited by other.
International Search Report for Co-Pending PCT Application U.S. Appl. No. PCT/US2007/08246 dated Apr. 9, 2008. cited by other.
Bolshaya Sovetskaya Entsiklopediya [The Big Soviet Enclyclopedia], M., 1976, vol. 25, p. 891. cited by other.
N.A. Tyukavkina, Yu. I. Baukov, Bioorganicheskaya khimiya [Bioorganic Chemistry], M., Meditsina, 1991, 54 pp. cited by other.
Office Action and translation thereof from Russian Application No. 200744612/04(048882), 11 pages, received Feb. 11, 2010. cited by other.
Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
1. A compound of the Formula I ##STR00311## and tautomers, and salts thereof, wherein: W is S(O).sub.m; m is 0, 1 or 2; R.sup.1 is (CH.sub.2).sub.3--NH.sub.2; Ar.sup.1 andAr.sup.2 are independently phenyl or a 5 or 6 membered heteroaryl ring having 1 to 3 heteroatoms independently selected from N, O and S, wherein said heteroaryl is a carbon radical and said phenyl and heteroaryl are optionally substituted with one ormore groups independently selected from halogen, cyano, nitro, azido, --OR.sup.10, --NR.sup.10R.sup.11, --NR.sup.10SO.sub.2R.sup.13, --SO.sub.2NR.sup.10R.sup.11, --C(.dbd.O)R.sup.10, --C(.dbd.O)OR.sup.10, --OC(.dbd.O)R.sup.10,--NR.sup.10C(.dbd.O)OR.sup.13, --NR.sup.10--C(.dbd.O)R.sup.11, --C(.dbd.O)NR.sup.10R.sup.11, --SR.sup.10, --S(O)R.sup.13, --SO.sub.2R.sup.13, --SO.sub.2NHC(.dbd.O)R.sup.10, --NR.sup.10C(.dbd.O)NR.sup.11R.sup.12, --NR.sup.10C(NCN)NR.sup.11R.sup.12,--NR.sup.10C(H)NR.sup.11R.sup.12, --NR.sup.10C(R.sup.13)NR.sup.11R.sup.12, --OP(.dbd.O)(OR.sup.10).sub.2, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl; R.sup.4 is selected from:##STR00312## R.sup.10, R.sup.11 and R.sup.12 independently are selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl and arylalkyl, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl andarylalkyl are optionally substituted with one or more groups independently selected from oxo (with the proviso that it is not on said aryl or heteroaryl portions), halogen, cyano, nitro, OR.sup.14, --NR.sup.14R.sup.15, trifluoromethyl, difluoromethoxy,trifluoromethoxy, azido, alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R.sup.13 is alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclyl or arylalkyl, wherein said alkyl, alkenyl, cycloalkyl,aryl, heteroaryl, heterocyclyl and arylalkyl are optionally substituted with one to three groups independently selected from oxo (with the proviso that it is not on said aryl or heteroaryl portions), halogen, cyano, nitro, OR.sup.14, --NR.sup.14R.sup.15,trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl, or any two of R.sup.10, R.sup.11, R.sup.12 and R.sup.13 together with the atoms to which theyare attached form a 4 to 10 membered heteroaryl or heterocyclic ring, wherein said heteroaryl and heterocyclic rings are optionally substituted with one to three groups independently selected from oxo (with the proviso that it is not on said heteroarylring), halogen, cyano, nitro, OR.sup.14, --NR.sup.14R.sup.15, trifluoromethyl, difluoromethoxy, trifluoromethoxy, azido, alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, heterocyclyl, and heterocyclylalkyl; R.sup.14 and R.sup.15 areindependently selected from hydrogen, alkyl, alkenyl, lower alkynyl, cycloalkyl, aryl, heteroaryl, heterocyclyl and arylalkyl, or R.sup.14 and R.sup.15 together with the atoms to which they are attached form a saturated, partially unsaturated or fullyunsaturated 5-6 membered heterocyclyl; R.sup.17, R.sup.22 and R.sup.23 are independently H or alkyl; R.sup.18 is H, OH, O-alkyl, CN, C(.dbd.O)NH.sub.2, C(.dbd.O)NH(alkyl), C(.dbd.O)N(alkyl).sub.2, C(.dbd.O)alkyl, or alkyl optionally substituted withone or more groups independently selected from halogen, CN, OH, O-alkyl, NH.sub.2, NH-alkyl, N(alkyl).sub.2 and aryl; R.sup.19 is H or alkyl optionally substituted with one or more groups independently selected from halogen, NO.sub.2, halogen, CN, OH,O-alkyl, NH.sub.2, NH-alkyl, N(alkyl).sub.2 and aryl; and R.sup.20 and R.sup.21 are independently H, C(.dbd.O)alkyl, or alkyl optionally substituted with one or more groups independently selected from halogen, CN, OH, O-alkyl, NH.sub.2, NH-alkyl,N(alkyl).sub.2 and aryl, or R.sup.20 and R.sup.21 together with the atoms to which they are attached form a 5-6 membered unsaturated or partially unsaturated heterocyclic ring, or R.sup.18 and R.sup.20 together with the atoms to which they are attachedform a 5-6 membered partially unsaturated or fully unsaturated heterocyclic ring, or R.sup.17 and R.sup.20 together with the atoms to which they are attached form a 5-6 membered unsaturated or partially unsaturated heterocyclic ring.
2. The compound of claim 1, wherein Ar.sup.1 is phenyl optionally substituted with one or more groups independently selected from halogen, alkyl, --OR.sup.10or --NR.sup.10R.sup.11; or Ar.sup.1 is a heteroaryl selected from thiophenyl orpyridyl, wherein said pyridyl is optionally substituted independently with one or more halogen.
3. The compound of claim 1, wherein Ar.sup.1 is phenyl, 2,4-difluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 2,5-dichlorophenyl, 2,3-dichlorophenyl, 3,4-dichlorophenyl, 3,5-dichlorophenyl, 2-chloro-5-fluorophenyl,2-fluoro-5-chlorophenyl, 2-chloro-5-methylphenyl, 2-trifluoromethyl-5-fluorophenyl, 2-fluoro-5-methoxyphenyl, thiophen-2-yl, thiophen-3-yl, 5-chlorothiophen-2-yl, 2-pyridyl, 3-pyridyl, 4-chloropyridin-3-yl, 3-chloropyridin-2-yl, 4-fluoropyridin-3-yl, or3,6-difluoropyridin-2-yl.
4. The compound of claim 1, wherein Ar.sup.1 is 2,4-difluorophenyl.
5. The compound of claim 1, wherein Ar.sup.2 is phenyl optionally substituted with one or more groups independently selected from halogen, OR.sup.10,NR.sup.10R.sup.11, CN, NO.sub.2, --OP(.dbd.O)(OR.sup.10).sub.2, C(.dbd.O)OR.sup.10, or Ar.sup.2is a heteroaryl selected from pyridyl, thiophenyl optionally substituted with alkyl, imidazolyl, and pyrazolyl optionally substituted with NR.sup.10R.sup.11.
6. The compound of claim 1, wherein Ar.sup.2 is phenyl, 2-methylphenyl, 3-methylphenyl, 4-methylphenyl, 3,4-dimethylphenyl, 3,5-dimethylphenyl, 2-ethylphenyl, 3-ethylphenyl, 4-t-butylphenyl, 2-chlorophenyl, 4-chlorophenyl, 3-fluorophenyl,4-fluorophenyl, 4-bromophenyl, 3,4-dichlorophenyl, 3-nitrophenyl, 3-hydroxyphenyl, 3-(OPO.sub.3H.sub.2)-phenyl, 3-aminophenyl, 3-carboxyphenyl, 3-cyanophenyl, 2-pyridyl, 3-pyridyl, 5-methylthiophen-2-yl, 2-methylthiazol-4-yl, 2-(1H-imidazol-2-yl),2-(1H-imidazol-4-yl) or 3-amino-1H-pyrazol-5-yl.
7. The compound of claim 1, wherein Ar.sup.2 is phenyl.
8. The compound of claim 1, wherein W is S.
9. The compound of claim 1, selected from the group consisting of: 3-(5-(2,5-difluorophenyl)-3-(oxazol-2-yl)-2-phenyl-2,3-dihydro-1,3,4-thia- diazol-2-yl)propan-1-amine; 3-(5-(2,5-difluorophenyl)-2-phenyl-3-(thiazol-2-yl)-2,3-dihydro-1,3,4-thi- adiazol-2-yl)propan-1-amine; 3-(5-(2,5-difluorophenyl)-3-(4-methylthiazol-2-yl)-2-phenyl-2,3-dihydro-1- ,3,4-thiadiazol-2-yl)propan-1-amine; 3-(5-(2,5-difluorophenyl)-3-(4-ethylthiazol-2-yl)-2-phenyl-2,3-dihydro-1,- 3,4-thiadiazol-2-yl)propan-1-amine; 5-(2-(3-aminopropyl)-5-(3-fluorophenyl)-2-phenyl-1,3,4-thiadiazol-3(2H)-y- l)-3,4-dihydropyrrol-2-one; 3-(5-(2,5-difluorophenyl)-3-(4,5-dihydrothiazol-2-yl)-2-phenyl-2,3-dihydr- o-1,3,4-thiadiazol-2-yl)propan-1-amine; 3-(5-(2,5-difluorophenyl)-3-(5-methyl-1,3,4-oxadiazol-2-yl)-2-phenyl-2,3-- dihydro-1,3,4-thiadiazol-2-yl)propan-1-amine; 3-(5-(2,5-difluorophenyl)-3-(5-ethyl-1,3,4-oxadiazol-2-yl)-2-phenyl-2,3-d- ihydro-1,3,4-thiadiazol-2-yl)propan-1-amine; Ethyl 2-(5-(2-(3-aminopropyl)-5-(2,5-difluorophenyl)-2-phenyl-1,3,4-thiadiazol-- 3(2H)-yl)-1,3,4-oxadiazol-2-yl)acetate; 5-(2-(3-aminopropyl)-5-(2,5-difluorophenyl)-2-phenyl-1,3,4-thiadiazol-3(2- H)-yl)-N-ethyl-1,3,4-oxadiazol-2-amine; 3-(5-(2,5-difluorophenyl)-2-phenyl-3-(1,3,4-thiadiazol-2-yl)-2,3-dihydro-- 1,3,4-thiadiazol-2-yl)propan-1-amine; 3-(5-(2,5-difluorophenyl)-3-(3-methyl-1,2,4-oxadiazol-5-yl)-2-phenyl-2,3-- dihydro-1,3,4-thiadiazol-2-yl)propan-1-amine; 3-(5-(2,5-difluorophenyl)-3(1-methyl-5-phenyl-1H-1,2,4-triazol-3-yl)-2-ph- enyl-2,3-dihydro-1,3,4-thiadiazol-2-yl)propan-1-amine; 3-(5-(2,5-difluorophenyl)-2-(4-fluorophenyl)-3-(5-methyl-1,3,4-thiadiazol- -2-yl)-2,3-dihydro-1,3,4-thiadiazol-2-yl)propan-1-amine; 3-(5-(2,5-difluorophenyl)-2-(3-fluorophenyl)-3-(5-methyl-1,3,4-thiadiazol--2-yl)-2,3-dihydro-1,3,4-thiadiazol-2-yl)propan-1-amine; 3-(2-(3-aminopropyl)-5-(2,5-difluorophenyl)-3-(5-methyl-1,3,4-thiadiazol-- 2-yl)-2,3-dihydro-1,3,4-thiadiazol-2-yl)phenol; and salts thereof.
10. A composition comprising a compound of claim 1, and a pharmaceutically acceptable carrier.
Driver model and assistance function evaluation apparatus and method for vehicle dynamics control system in which driver model is equipped
Inhaler apparatus using a tribo-electric charging technique
Belt sander with control bar
Size for production of a BN-containing coating, method for production thereof, coated body production and use thereof
Amidino compounds, their manufacture and methods of treatment
Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-alzheimer agents
Box spring stapler apparatus
Head-mounted optical direct visualization system
Controlled release urea-based products